Cell engineering

Gameto Unveils New Data on In Vitro Maturation Product Candidate Fertilo During Four Presentations at the 2023 American Society for Reproductive Medicine

Retrieved on: 
Thursday, October 19, 2023
Gold, Human, Cell engineering, Fertility, RMA, IVM, RNA, Biotechnology, Spindle apparatus, Congress, Research, Society, F1, Reproductive medicine, IVF, Egg, Oocyte, Cell, Partnership, Behavior informatics, Abstract, American Society for Reproductive Medicine, ASRM, Woman, Safety, Patient, Gene expression, Mineral oil

Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.

Key Points: 
  • Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.
  • The combined findings are an important evidence package as a next step in advancing this reproductive technology.
  • NEW YORK, Oct. 19, 2023 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, presented four abstracts at the 2023 American Society for Reproductive Medicine (ASRM) Congress.
  • The findings show that Fertilo not only matures more eggs, but results in better gene expression and genetic health quality than traditional IVM.

Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit

Retrieved on: 
Tuesday, October 17, 2023
Health, NYSE, Biology, Cell engineering, DNA, Therapy, Persephone, Environment, Bacteroides, SAN, Software, Commercial, Medical imaging, Antibiotics, Ginkgo

SAN DIEGO and BOSTON, Oct. 17, 2023 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient health through the microbiome, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of their first collaboration together, a Bacteroides engineering toolkit. Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit. Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.

Key Points: 
  • Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit.
  • Persephone will utilize the technology to develop a pipeline of microbiome therapeutics, and Ginkgo can use the technology as part of its broader platform offering for future customers.
  • The technology comprises a set of generalizable genetic tools which can facilitate rapid Bacteroides engineering, including in the high-throughput anaerobic engineering context.
  • Over the course of this collaboration, Ginkgo incorporated its flagship hardware and software workflows under an anaerobic blanket, meaningfully extending its cell engineering platform capabilities to perform productively in an anaerobic environment.

Zenfold Leverages Ginkgo Enzyme Services to Enable Veterinary Active Ingredient Development with Sustainable Biology

Retrieved on: 
Monday, October 16, 2023
Partnership, DNA, A-DNA, Cell engineering, NYSE, Veterinary medicine, Environment, SVP, Biotechnology, Commercial, Fine chemical, Ginkgo

This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.

Key Points: 
  • This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.
  • "This collaboration marks a significant step forward in Zenfold's mission to bring sustainable manufacturing technology to the veterinary medicine industry," said Dr. BSV Prasad, CEO and Managing Director of Zenfold Sustainable Technologies.
  • "We are excited to partner with Zenfold, which brings a powerful vision of sustainable biotechnology to veterinary active ingredient development.
  • To learn more about the end-to-end services included in Ginkgo Enzyme Services, visit our webpage or email us at [email protected] .

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

Retrieved on: 
Wednesday, October 4, 2023
GMP, IPSC, Oocyte, Biotechnology, Medicines and Healthcare products Regulatory Agency, IVF, European Medicines Agency, Patient, Cell engineering, Health, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceuticals and Medical Devices Agency, Pharmaceutical industry

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechnology company with a mission to redefine women's healthcare, a non-exclusive right to use REPROCELL's StemRNA™ Clinical Seed iPSCs. The clinical-grade iPSC line will be used for the development and commercialization of Gameto's program to improve the IVF and egg freezing process, Fertilo. Terms of the agreement were not disclosed.

Key Points: 
  • Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.
  • The clinical-grade iPSC line will be used for the development and commercialization of Gameto's program to improve the IVF and egg freezing process, Fertilo.
  • "We are thrilled to partner with Gameto to enable and support their program, Fertilo.
  • "Women using these current services are still subject to dozens of hormonal injections and the associated side effects and complications.

Sphere Fluidics’ Cyto-Mine System Selected by FairJourney Biologics to Advance Cell Line Development Workflows

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Pharmaceutical, Health, Medical Devices, Immortalised cell line, GLP, Sphere Fluidics, Therapy, Research, Sphere, Engineering, Drug discovery, Title 21 CFR Part 11, Knowledge, Cell engineering, FDA, Synthetic biology, Vaccine

FairJourney Biologics has adopted the platform as part of the launch for its latest cell line development services, to streamline and accelerate customer workflows.

Key Points: 
  • FairJourney Biologics has adopted the platform as part of the launch for its latest cell line development services, to streamline and accelerate customer workflows.
  • FairJourney Biologics’ team of experts comprises an extensive knowledge of cellular biology, enabling them to tailor cell lines precisely to their partners' unique requirements.
  • Leveraging state-of-the-art technologies and meticulous quality control measures, FairJourney Biologics consistently delivers high-performing, stable cell lines that serve as the foundation for efficient antibody production and therapeutics development.
  • The integration of Sphere Fluidics’ Cyto-Mine platform into our cell line development workflows enables us to best cater to our partners’ needs, to provide high-quality, customized cell lines in a fraction of the time.”

SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors

Retrieved on: 
Tuesday, September 26, 2023
DNA, AACR, CGA, American Association for Cancer Research, Biotechnology, Acquisition, OTC, Cell engineering, Gene, IBN, Vaccine, Beauty salon, Medical device

With this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023.

Key Points: 
  • With this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023.
  • ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome.
  • Gene-editing companies will use ABBIE kits to deliver a gene payload to a specific locus on their targeted cells.
  • The remaining $4 million payment to CGA 369 will be triggered by ABBIE’s first $50 million of commercial sales.

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Retrieved on: 
Tuesday, September 19, 2023
Research, Technology, Infectious Diseases, Stem Cells, Biotechnology, Pharmaceutical, Robotics, Health, Science, Other Science, Cell biology, University of Colorado Colorado Springs, University, Therapy, CSO, RTA, Cancer, Eric Schmidt, Innovation, Antibody, DARPA, Li Ka-shing, Machine learning, Engineering, Cell engineering, SVP, Independent Board for Presbyterian Foreign Missions, Pfizer, Disease, Fine chemical, Vaccine

BioLoomics , the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs.

Key Points: 
  • BioLoomics , the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs.
  • He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies.
  • “Our mission is to make safer, more effective cancer therapeutics by hijacking how human proteins move antibodies around the cell,” said Dr. Douglas Chapnick, founder and CEO of BioLoomics.
  • With this new capital, BioLoomics will develop pre-clinical assets and form strategic partnerships with large pharma companies.

Mission Bio Launches Tapestri® Genome Editing Solution for Deeper Analysis of Advanced Therapies

Retrieved on: 
Tuesday, September 12, 2023
CRISPR, University, Gene, Gene editing, Business, American Society of Gene and Cell Therapy, Single cell, Genomics, Cell, Doctor of Philosophy, Associate, B cell, HIV disease progression rates, Patient safety, Cell engineering, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Medical imaging, Vaccine, Antibiotics, Medicine

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2023 /PRNewswire/ -- Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, today launched the Tapestri® Genome Editing Solution. Designed to meet the pressing need for high-resolution analysis of genome editing, this first-of-its-kind solution addresses a long-standing gap in advanced therapy development, disease modeling, and functional genomics. Already drawing substantial interest from key opinion leaders in pharmaceuticals, academia, and government labs, this much-anticipated solution was initially previewed at The American Society of Gene and Cell Therapy annual conference.

Key Points: 
  • Designed to meet the pressing need for high-resolution analysis of genome editing, this first-of-its-kind solution addresses a long-standing gap in advanced therapy development, disease modeling, and functional genomics.
  • The Tapestri® Genome Editing Solution has numerous applications for genome engineers, advanced therapy developers, and disease modelers.
  • The solution also supports multi-omic analysis — co-measuring editing and cell-surface protein expression in the same cells.
  • "The Tapestri Genome Editing Solution equips researchers with the capability to scrutinize gene therapies at the single-cell level, a crucial step for ensuring patient safety," said Brittany Enzmann, PhD, Product Manager for Mission Bio's Tapesti® Genome Editing Solution.

Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies

Retrieved on: 
Thursday, August 24, 2023
Partnership, Genetic engineering, Gene editing, Cell, Patient, Engineering, Cell engineering, R, Safety, Synthetic biology, Genome, Vaccine, Antibiotics

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies.

Key Points: 
  • Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies.
  • bit.bio aims to leverage technology to increase efficiency of human cell engineering and accelerate the development of highly scalable cell therapies that are capable of treating millions of patients.
  • The partnership will apply Synthego's expertise in gene editing to bit.bio's opti-oxTM precision cell programming technology, with the aim of discovering and developing advanced genetic engineering solutions for cell therapies.
  • We are thrilled to deepen our partnership with bit.bio to facilitate a leap forward in the development of synthetic biology-based cell therapies," said Paul Dabrowski, CEO at Synthego.

Mekonos Appoints Benjamin Borgo as Chief Operating Officer

Retrieved on: 
Wednesday, August 9, 2023
Technology, Semiconductor, Genetics, Nanotechnology, Stem Cells, Biotechnology, Health, Other Science, Science, San Francisco State University, MBA, Borgo, Washington University in St. Louis, Doctor of Philosophy, Patient, Agilent Technologies, Biology, Growth, Cell engineering, Mathematics, Management, Fine chemical, Ichneutica inscripta

Mekonos, Inc. , a biotech platform company building the future of cell therapies on a chip, today announced the appointment of Benjamin Borgo, MBA, PhD, as chief operating officer.

Key Points: 
  • Mekonos, Inc. , a biotech platform company building the future of cell therapies on a chip, today announced the appointment of Benjamin Borgo, MBA, PhD, as chief operating officer.
  • Dr. Borgo reports to Anil Narasimha, PhD, co-founder, chief executive officer of Mekonos.
  • “We are delighted to welcome Ben to the Mekonos leadership team during this important phase of the company’s growth,” Dr. Narasimha said.
  • “I am excited to join Mekonos as I strongly believe in its mission to ensure that more patients can benefit from cell and gene therapies,” Dr. Borgo said.